

LIST OF FIGURES

Fig. No.	Figure Legends	Page No.
1.1	Synthesis of ACh and cholinergic neurotransmission.	5
1.2	The amyloidogenic pathway and its manifestations leading to dementia.	6
1.3	Schematic illustration of tau aggregation and formation of NFTs	8
3.1	Design strategy for Part-I (Series I and II) ligands	32
3.2	Design strategy for Part-II (Series III and IV) ligands.	33
5.1	Lineweaver-Burk plot for the kinetic study of hAChE inhibition by compound 6j .	69
5.2	Dixon plot of compound 6j at three different concentrations (0.035, 0.070, and 0.105 μM) showing K_i value of inhibitor as the negative intersection at the x-axis.	69
5.3	Results of thioflavin T assay for compounds 6j and 6k in [A] self-induced; [B] AChE-induced experiments.	72
5.4	The results of % anti-A β aggregation activity in thioflavin T assay.	72
5.5	The effect of compounds 6j and 6k on neuroprotective ability on SH-SY5Y neuroblastoma cell lines.	73
5.6	The effect of compounds 6j and 6k on scopolamine-induced amnesia model by Y maze test in rats. [A] Percentage spontaneous alterations and; [B] total arm entries.	74
5.7	Effect of 6j in learning and memory improvement by ICV A β rat model by Morris water maze test; [A] ELT and; [B] total platform crossings.	76
5.8	<i>Ex-vivo</i> study of compounds 6j and 6k to assess the levels of; [A] AChE; [B] MDA and; [C] SOD.	77
5.9	Validation experiment showing re-docked (pink) and co-crystallized (blue) poses of donepezil on 4EY7 (RMSD = 0.3496 Å).	79
5.10	Validation experiment showing re-docked (pink) and co-crystallized (blue) poses of F1M on 2ZJM (RMSD = 1.1903 Å).	80
5.11	The molecular docking study of 6j on AChE. [A] 3D and [B] 2D docked poses.	80
5.12	The molecular docking study of 6j on BACE-1. [A] 3D and [B] 2D docked poses.	80
5.13	Enzyme kinetics study of compound 13o against hAChE showing mixed-type of inhibition Lineweaver-Burk plot.	97
5.14	Dixon plot determined the dissociation constant K_i of compound 13o at three different concentrations (0.025, 0.050, and 0.075 μM).	97
5.15	The results of % Anti-A β aggregation activity in thioflavin T assay [A] self- and; [B] AChE-induced experiments.	100
5.16	The results of thioflavin T assay by compound 13n and 13o ; [A] self- and; [B] AChE-induced experiments.	100

Fig. No.	Figure Legends	Page No.
5.17	AFM visualized images at 5 μm scale for the sample of A β in the presence or absence of inhibitor 13o over 7 days.	101
5.18	Neuroprotective activity of compounds 13n and 13o against A β -induced oxidative stress in SH-SY5Y cell lines by MTT assay.	102
5.19	The effect of compounds 13n and 13o (2.5, 5, 10 mg/kg) in Y-maze test [A] % spontaneous alternation; [B] total arm entries.	103
5.20	Assessment of improvement in learning and memory impairment by compound 13o in Morris water maze test; (A) escape latency time (ELT); (B) numbers of platform crossings.	105
5.21	The <i>ex-vivo</i> and biochemical analysis of compounds 13n and 13o in hippocampal brain homogenates; [A] AChE activity; [B] level of MDA in TBARS assay and; [C] SOD activity.	106
5.22	2D docked pose of compound 13o on; [A] hAChE (4EY7) and; [B] hBACE-1 (2ZJM)	108
5.23	Docking poses of compound 13o in active sites of; [A] hAChE (4EY7). [B] hBACE-1 (2ZJM);	108
5.24	The ligand-protein RMSD relative to protein backbone structure for compound 13o against; [A] hAChE (4EY7) and; [B] hBACE-1 (2ZJM).	110
5.25	Molecular dynamics simulation study of the docked complex of 13o -hAChE; [A] graphical representation showing percentage interaction; [B] histogram showing interaction fractions; [C] time-line representation showing active site binding interaction with each amino acid residues for a total simulation run time of 40 ns.	110
5.26	Molecular dynamics simulation study of the docked complex of 13o -hBACE-1; [A] graphical representation showing percentage interaction; [B] histogram showing interaction fractions; [C] time-line representation showing active site binding interaction with each amino acid residues for a total simulation run time of 40 ns.	111

LIST OF SCHEMES

Scheme No.	Scheme Legends	Page No.
1	Synthesis of compounds from Series I (5a–o) and Series II (6a–o).	35
2	Synthesis of compounds from Series III (12a–o) and Series IV (13a–o).	37